Midazolam nasal spray trial meets primary endpoint in patients with seizure clusters

Proximagen Ltd. said today that its pivotal Phase III trial of intranasal midazolam met its primary efficacy endpoint as a treatment for patients with seizure clusters. The Cambridge-based company said it plans to begin talks with the FDA for a New Drug Application in the 2nd half of this year based on the trial’s findings.

The company’s USL261 formulation was developed for intranasal delivery in patients who require control of intermittent bouts of heightened seizure activity.

Get the full story at our sister site, Drug Delivery Business News.

The post Midazolam nasal spray trial meets primary endpoint in patients with seizure clusters appeared first on MassDevice.

from MassDevice http://ift.tt/2ppVLCb